Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO WCGIC 2020 | First-line durvalumab + monalizumab in microsatellite-stable CRC

Zev Wainberg, MD, of Ronald Reagan UCLA Medical Center, Los Angeles, CA, explores the use of first-line durvalumab and monalizumab, mFOLFOX6, and bevacizumab or cetuximab for metastatic microsatellite-stable colorectal cancer (CRC). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology)